Only 0.01% of drug candidates entering clinical trials reach the market. With Charles River supporting >80% of drugs approved by the FDA over the last three years, improve your odds, leverage our experience, and expedite your time to market.
Our comprehensive portfolio supporting proteins, antibodies, vaccines, and cell and gene therapies includes:
Cell and Gene Therapy CDMO Solutions
Cell Bank and Virus Manufacturing
Biophysical, Molecular, and Genetic Characterization Services
Biosafety and Viral Clearance Studies
Bioactivity and Potency Testing
Stability and QC Testing
To learn how we can help to get your product to patients faster, visit criver.com/biologics.